autologous blood and marrow transplantation - Blog Science ...

Abonour et al. 393
DFS by Prognostic Category
o.o v 10 20 30
Category
Good
Intermediate
Months of DFS
cnsr
22
3
event
10
14
40
tot
32
17
1
I 1
50
median
Figure 1 • Disease-free survival based on prognostic category. Scores were calculate
giving 1 point each for progressive or refractory disease before HDCT and 2 points fo
absolute refractory disease or HCG >1000 before HDCT. 17
7.2
T
60
Thirty-two patients had a sco
ofO (good risk category), and 17 patients scored 1-2 (intermediate risk group). Median s
vival was Hot reached for the good category group.
is of interest that six of the nine patients who had a partial response to first-line
therapy and persistent elevation of their tumor marker were cured after HDCT,
while one of the four patients who were cisplatin refractory was cured. Based on
the multivariate analysis of prognostic factors, 32 patients were in the good
category group and 17 patients were in the intermediate group (Fig. 1) According
to this prognostic model, 1 point is given for progressive or refractory disease
before high-dose chemotherapy and 2 points for absolute refractory disease or
HCG >1000 before HDCT. Of the 32 patients in the low-risk category, 72% are
currently free of disease compared with only 29% of those in the intermediate
category. Ninety-one of the 98 planned cycles of HDCT were given with limited
toxicity. Febrile neutropenia was seen in 58% of the cycles and documented
infection in 18% of the cycles. Grade 3-4 gastrointestinal toxicity rate was 39%